Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal ...

Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...

Delays in diagnosis, long waits for operations may explain trend ...

Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Edwards Lifesciences (NYSE:EW) is ending its planned acquisition of JenaValve. The company is redirecting the capital that ...

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

Annual Meeting, investigators presented a late-breaking study focused on surgical aortic valve replacement (SAVR) following ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

While doctors may recommend medications and lifestyle changes to support overall heart health, these approaches cannot stop ...

While many people fear a cancer diagnosis above all else, clinical data reveals that symptomatic aortic stenosis, a severe ...